Swissmedic only issues WHO Certificates in Accordance with the new Format

Recommendation
30 June 2025
A CPP (Certificate of a Pharmaceutical Product) certifies the marketability of a medicinal product in the country of origin. The certificates are issued by the authority of the country where the medicinal product is manufactured and authorised (exporting country). These can then serve competent authorities of importing third countries in the following regulatory situations:
- In the context of applications for marketing authorisation
- In the context of applications for renewal, extension, variation or review of a marketing authorisation.
The WHO (World Health Organisation) recommends the use of a standardised format for this certificate.
From 20 March 2023, Swissmedic will issue CPPs in the new WHO format (according to TRS 1033 - 55th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations; Annex 9). The changes are detailed in the new version of guidance document BW302_00_001e.
No CPP orders can be accepted during the transition (13 to 19 March 2023) to the new format. Orders for CPPs in the old format can be submitted via the portal until 12 March 2023. From 20 March 2023, new orders can only be submitted using the new input file. The new version of guidance document BW302_00_001e and the new input file will be available on the Swissmedic website from 13 March 2023.
Source: Swissmedic
Related GMP News
28.05.2025A View on the EU Critical Medicines Act to secure Pharma Supply Chains
20.05.2025Summary Data on Registration and Listing of Cosmetic Facilities and Products
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports